Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Fluoxetine-rapid dissolve - Autism Therapeutics

Next Previous
Drug Profile

Fluoxetine-rapid dissolve - Autism Therapeutics

Alternative Names: AT 001 - Autism Thereapeutics; AT001 - Autism Therapeutics; NPL-2008; ODT fluoxetine - Autism Therapeutics; Serelsa; Zydis™ ODT fluoxetine

Latest Information Update: 10 Dec 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Mount Sinai School of Medicine
  • Developer Autism Therapeutics
  • Class Antidepressants; Anxiolytics; Behavioural disorder therapies; Eye disorder therapies; Propylamines; Small molecules
  • Mechanism of Action Serotonin uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Autistic disorder
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Autistic disorder

Most Recent Events

  • 03 Sep 2021 Discontinued - Phase-II for Autistic disorder (In adults) in USA (PO)
  • 03 Sep 2021 Discontinued - Phase-III for Autistic disorder (In adolescents, In children) in USA (PO)
  • 19 Sep 2017 Fluoxetine-rapid dissolve is still at phase III development stage for Autistic disorder (in adolescents and children) and at phase II development stage (in adults) in USA (PO) (Autism Therapeutics pipeline, September 2017)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top